THE INFLUENCE OF INHIBITORS OF TUMOUR NECROSIS FACTOR-ALPHA ON THE CLINICAL COURSE OF RHEUMATOID UVEITIS AND DYNAMICS OF IMMUNOLOGICAL CHARACTERISTICS

Abstract

The present study included 34 children aged from 4 to 16 years presenting with uveitis associated with rheumatoid diseases, such as juvenile idiopathic arthritis (n = 32) and Behcet’s disease (n = 2). The levels of tumour necrosis factor-alpha (TNF-alpha) in blood sera (BS) and lacrimal fluid (LF) were measured in the patients differing in the activity of the inflammatory processes in the eyes within a period from 4 days to 2 years 9 months after the onset of the treatment with TNF-alpha inhibitors (infliximab and adalimumab). A total of 57 BS samples and 27 LF samples taken from the affected eyes were available for the analysis. Active uveitis was diagnosed in 76.9% of the 26 cases in the absence of TNF-alpha in BS and in 35.5% of the 31 cases at the cytokine levels from 2 to 21 pg/ml (i.e. the two-fold difference, p < 0.01). The analogous results were obtained by the measurement of TNF-alpha in LF. Its absence in LF was associated with the inflammatory process in 84.6% of the 13 cases and 14.3% of the 14 cases at the cytokine level from 2 to 10 pg/ml (p < 0.001). Remission of uveitis was most frequently achieved in the patients having low TNF-alpha concentrations in both fluids. It means that remission of uveitis may be achieved and maintained by the reduction of TNF-alpha concentrations in BP and LF to an optimal minimal level; there is no need to completely suppress its secretion. It is concluded that immunological monitoring facilitates the correction of the treatment and the improvement of the outcome of the disease.

Keywords

uveitis / cytokines / tumour necrosis factor-alpha / juvenile idiopathic arthritis / Behcet’s disease

References

[1] Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. — М., 2007.

[2] Денисова Е.В., Катаргина Л.А., Старикова А.В., Любимова Н.В. Генно-инженерные биологические препараты в комплексном лечении педиатрических увеитов, ассоциированных с ревматическими заболеваниями // Тезисы 2-го Всероссийского конгресса ревматологов России. — Ярославль, 2011. — С. 20.

[3] Дроздова Е.А., Теплова С.Н. Роль цитокинов в иммунопатогенезе увеита, ассоциированного с ревматическими заболеваниями // Цитокины и воспаление. — 2007. — № 1. — С. 15—19.

[4] Катаргина Л.А., Хватова А.В. Эндогенные увеиты у детей и подростков. — М., 2000.

[5] Катаргина Л.А., Архипова Л.Т. Увеиты: патогенетическая и иммуносупрессивная терапия. — Тверь, 2004.

[6] Михельс М., Никишина И.П., Федоров Е.С., Салугина С.О. Генно-инженерная биологическая терапия ювенильного артрита // Науч.-практ. ревматол. — 2011. — № 1. — С. 78—93.

[7] Слепова О.С. Патогенетическая роль цитокинов при различных заболеваниях глаз как основа для прогнозирования и выбора тактики иммунокорригирующего лечения // Рос. офтальмол. журн. — 2008. — № 3. — С. 36—42.

[8] Старикова А.В. Клинические и иммунологические критерии прогнозирования течения, исходов и выбора лечебной тактики при увеитах, ассоциированных с поражением суставов у детей: Автореф. дис.. канд. мед. наук. — М., 2003.

[9] Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families // N. Engl. J. Med. — 1996. — Vol. 334, N 26. — P. 1717—1725.

[10] Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood // Br. J. Ophthalmol. — 2007. — Vol. 91, N 3. — P. 319—324.

[11] Gallagher M., Quinones K., Cervantes-Cast. R. et al. Biological response modifier therapy for refractory childhood uveitis // Br. J. Ophthalmol. — 2007. — Vol. 91, N 10. — P. 1341—1344.

[12] Heiligenhaus A., Mingels A., Heinz C., Gasner G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication // Eur. J. Ophthalmol. — 2007. — Vol. 17, N 15. — P. 743—748.

[13] Lacomba M.S., Martin С.M., Galera G.J.M. et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis // Ophthalm. Res. — 2001. — Vol. 33, N 5. — P. 251—255.

[14] Saurenmann R.K., Levin A.V., Rose J.B. et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis // Rheumatology. — 2006. — Vol. 45, N 8. — P. 982—989.

[15] Tappeiner C., Roesel M., Heinz C. et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis // Eye. — 2009. — Vol. 23, N 5. — P. 1192—1198.

[16] Tynjälä P., Kotaniemi K., Linahl P. et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis // Rheumatology. — 2007. — Vol. 47. — P. 339—344.

RIGHTS & PERMISSIONS

Eco-Vector